Impaired stem cell function of CD34+ cells selected by two different immunomagnetic beads systems

Leukemia

Volumn 18, Issue 3, 2004, Pages 566-574

  Kimura, T ^a   Minamiguchi, H ^a,b   Wang, J ^a   Kaneko, H ^c   Nakagawa, H ^d   Fujii, H ^d   Sonoda, Y ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

CD34+ cells; Isolex 50; MiniMACs; SCID repopulating cell; Transplantation

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PURIFICATION; ARTICLE; BONE MARROW; CELL ACTIVITY; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL LINEAGE; CELL POPULATION; CELL SELECTION; CHILD; CLINICAL ARTICLE; COLONY FORMING CELL; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; IN VIVO STUDY; INTERMETHOD COMPARISON; LEUKAPHERESIS; MALE; MEDICAL RESEARCH; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL SEPARATION; CLONOGENIC ASSAY; INFANT; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PHYSIOLOGY;

ADULT; ANIMALS; ANTIGENS, CD34; ANTIGENS, CD45; BONE MARROW; CELL SEPARATION; COLONY-FORMING UNITS ASSAY; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOMAGNETIC SEPARATION; INFANT; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED;

EID: 1542503923     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403211     Document Type: Article

References (36)

1. Krause DS, Fackler MJ, Civin CI, May WS. CD34. Structure, biology, and clinical utility. Blood 1996; 87: 1-13.
2. + peripheral blood progenitor cells (PBPC). Stem Cells 2000; 18: 87-92.
3. + cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection. J Hematother 1998; 7: 175-183.
4. + peripheral blood stem cells: Retained engrafment capability and reduced tumor cell content. Br J Haematol 1999; 104: 382-391.
5. Mapara MY, Korner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337-344.
6. Dreger P, Viehmann K, von Neuhoff N, Kruss D, Glass B, Kneba. M et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol 2000; 28: 1187-1196.
7. + cells. Cytotherapy 2001; 3: 285-294.
8. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
9. + cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
10. + cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant 2001; 28: 849-857.
11. Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L et al. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 2001; 28: 1023-1029.
12. Prince HM, Bashford J, Wall D, Rischin D, Parker N, Toner GC et al. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy 2002; 4: 137-145.
13. + cells using the CliniMACS device. J Hematother 1999; 8: 209-218.
14. + cell enrichment for autologous peripheral blood stem cell transplantation by use of the. CliniMACS device. J Hematother Stem Cell Res 2000; 9: 557-564.
15. Rosen O, Thiel A, Massenkeil G, Hiepe F, Haupl T, Radtke H et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000; 2: 327-336.
16. + cell-selection systems. Transfusion 2001; 41: 783-789.
17. Prince HM, Wall D, Rischin D, Toner GC, Seymour JF, Blakey D et al. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy 2002; 4: 147-155.
18. Larochelle A, Vormoor J, Hanenberg H, Wang JCY, Bhatia M, Lapidot T et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat Med 1996; 2: 1329-1337.
19. Kuzuyama Y, Sonoda Y, Sakabe H, Nakagawa H, Fujii H, Abe T. Successful collection of peripheral blood stem cells mobilized by a combination of G-CSF with high-dose Ara-C or high-dose etoposide. Jpn J Clin Hematol 1993; 34: 1525-1531.
20. Takaue Y, Watanabe T, Kawano Y, Koyama T, Abe T, Suzue T et al. Isolation and storage of peripheral blood hematopoietic stem cells for autotransplantation into children with cancer. Blood 1989; 74: 1245-1251.
21. Minamiguchi H, Kimura T, Urata Y, Miyazaki H, Bamba T,-Abe T et al. Simultaneous signalling through c-mpl, c-kit, and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the P13-K, PKC and MAPK pathways. Br J Haematol 2001; 115: 175-185.
22. Philpott NJ, Turner AJC, Scopes J, Westby M, Marsh JCW, Gordon-Smith EC et al. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87: 2244-2251.
23. Kimura T, Sakabe H, Tanimukai S, Abe T, Urata Y, Yasukawa K et al. Simultaneous activation of signals through gp130, c-kit, and interleukin-3 receptor promotes a trilineage blood cell production in the absence of terminally acting lineage-specific factors. Blood 1997; 90: 4767-4778.
24. + highly purified blood progenitors expressing HLA-DR or different levels of c-kit protein. Blood 1994; 84: 4099-4106.
25. Ohmizono Y, Sakabe H, Kimura T, Tanimukai S, Matsumura T, Miyazaki H et al. Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia 1997; 11: 524-530.
26. Tanimukai S, Kimura T, Skabe H, Ohmizono Y, Kato T, Miyazaki H et al. Recombinant human c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential progenitors in vitro. Exp Hematol 1997; 25: 1025-1033.
27. Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 1989; 17: 145-153.
28. - cells: Correlation between long-term culture-initiating cells and telomerase expression. Leukemia 1998; 12: 728-734.
29. Breems DA, Blockland EAW, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994; 8: 1095-1104.
30. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998; 4: 1038-1045.
31. Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y et al. SCID-repopulating cell activity of human cord blood-derived CD34-negative cells assured by intra-bone marrow injection. Blood 2003; 101: 2924-2931.
32. Kaneko H, Kimura T, Tsuda S, Ohkawara Y, Abe T, Sonoda Y. CD34-positive cell selection using an Isolex 300 system in patients with solid tumors and its application for autologous peripheral blood stem cell transplantation. Jpn J Clin Hematol 1998; 39: 652-657.
33. + cells expressing different levels of HLA-DR, CD33, CD38, and c-kit antigens. Stem Cells 1997; 15: 73-81.
34. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242-245.
35. + cells. Exp Hematol 1998; 26: 353-360.
36. + stem cell transplantation. Bone Marrow Transplant 2001; 28: 587-595.